The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis
|
|
- Anissa Park
- 6 years ago
- Views:
Transcription
1 The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis Daniel Giddings, PharmD PGY-1 Pharmacy Practice Resident St. David's South Austin Medical Center October 4, 2013 Learning Objectives: 1. Describe the diagnostic criteria, pathogenesis and epidemiology of hepatorenal syndrome and spontaneous bacterial peritonitis (SBP). 2. Compare treatment guidelines for the use of albumin for the prevention of hepatorenal syndrome in SBP. 3. Examine the evidence base for use of albumin in these patients. 4. Determine albumin's role in the prevention of hepatorenal syndrome in SBP patients. 1
2 Hepatorenal Syndrome Introduction 1 Renal failure in patients with cirrhosis is relatively common, and can be attributed in some to dehydration or intrinsic renal parenchymal disease such as glomerulonephritis. In other cases, however, renal failure is not accompanied by any underlying renal pathology and cannot be attributed to other factors; this is known as hepatorenal syndrome. Diagnosis 1 Entirely a diagnosis of exclusion in patients with cirrhosis and ascites with associated renal impairment Treatment guidelines both reference diagnostic criteria put out by the International Ascites Club, updated last in 2007 The six criteria are: o Presence of cirrhosis with ascites o Renal impairment, as indicated by a serum creatinine of greater than 1.5mg/dL o No improvement in renal impairment (reduction in serum creatinine to < 1.5mg/dL) despite diuretic withdrawal and volume expansion with albumin (1g/kg actual body weight up to 100g) for 2 days o Absence of shock o No current or recent treatment with nephrotoxic drugs, such as aminoglycosides o Absence of parenchymal kidney disease as indicated by proteinuria of more than 500mg/day, microhematuria (> 50 RBC/hpf), and/or abnormal renal ultrasound Can be separated into two dynamic classes o Type 1 - A doubling in serum creatinine that reaches at least 2.5mg/dL over the course of at least two weeks o Type 2 - Cases that meet diagnostic criteria without meeting the criteria for Type 1 hepatorenal syndrome Pathogenesis 1,2 Centers around extreme renal vasoconstriction as a result of pathological splanchnic vasodilation The underlying cirrhotic process causes increased splanchnic vascular resistance and portal hypertension This leads to a decrease in systemic vascular resistance (SVR) through local release of vasodilators, including nitric oxide (NO), carbon monoxide, and endogenous cannabanoids o Bacterial translocation from the intestines may also play a role through the inflammatory response (could explain the relationship to SBP) Initially, cardiac output is increased to compensate for this decrease in vascular resistance (recall the formula: BP = SVR x CO) As portal hypertension and decrease in SVR progress, vasoconstrictor systems activate to keep blood pressure normal, including the RAAS system, the sympathetic nervous system, and the release of ADH These systems cause intense vasoconstriction in the renal arteries, leading to renal hypoperfusion, salt and water retention, and renal failure 2
3 Portal Hypertension Caused by underlying cirrhosis, leads to increased vascular resistance in splanchnic system Splanchnic Vasodilation Reponse to underlying cirrhosis and portal hypertension Compensatory Response Includes increased cardiac output and activation of vasoconstricting systems, including RAAS, ADH, and sympathetic nervous system activation Renal failure and Hepatorenal Syndrome Due to extreme vasoconstriction of the renal arteries mediated by the compensatory response Precipitating Factors 1 Bacterial infection, including spontaneous bacterial peritonitis (SBP) o SBP is the only infection with a clearly demonstrated relationship to hepatorenal syndrome Large-volume paracentesis without volume repletion Gastrointestinal bleeding Hypovolemic shock Over-diuresis (no study evidence for this) Epidemiology and Prognosis Overall incidence of hepatorenal syndrome was estimated to be 40% at 5 years in one study Renal failure in patients with cirrhosis and ascites is associated with a poor prognosis, but the development of hepatorenal syndrome indicates an even poorer one 3
4 Probability of survivial in cirrhotic patients with different renal impairments. SBP Diagnosis 3,4,5,6 Presentation is variable, and may include fever (mostly commonly), abdominal pain, altered mental status, diarrhea, or paralytic ileus Patients may be asymptomatic; thus diagnostic paracentesis should be performed in all patients who: o Have new-onset ascites o Develop symptoms such as unexplained encephalopathy or renal failure o Are stable, but suddenly deteriorate A PMN count > 250 cells/mm 3 is diagnostic of SBP Pathogenesis 3,4 Still unclear, but thought to be due to the translocation of bacteria from the intestinal lumen to the mesenteric lymph nodes, and thus to the peritoneum o Intestinal dysmotility and subsequent bacterial overgrowth may contribute o Oxidative stress and decreased bile acid synthesis may lead to increased permeability of the intestinal walls to bacteria and bacterial products (endotoxin, bacterial DNA) Could also be due to bacteremia from urinary or respiratory tract infections Cirrhotic patients are generally more susceptible to infections Risk Factors 3,4 GI bleeding Prior episode of SBP Ascitic fluid albumin concentrations of less than 1g/dL 4
5 Epidemiology and Mortality 3,4,5,6 Prevalence studies from the 1970's showed a prevalence of 5-10%, but newer studies using modern diagnostic criteria show a prevalence of roughly 10-30% of patients admitted to hospitals with cirrhosis In-hospital mortality rates have fallen from 90% to around 10-30% o Renal impairment is a strong predictor of mortality; progressive renal failure was associated with an in-hospital mortality of 100% in one study, with stable renal impairment being associated with a 31% mortality rate and no renal impairment only 7% o Other predictors of mortality include elevated BUN and serum bilirubin, positive ascitic fluid cultures, and age Treatment Guidelines 5,6 Two regularly updated guidelines that address the treatment and prevention of hepatorenal syndrome: o The American Association for the Study of Liver Diseases (AASLD) o The European Association for the Study of the Liver (EASL) AASLD Guidelines Class IIa, Level B Patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm 3 (0.25 x 10 9 /L) and clinical suspicion of SBP, who also have a serum creatinine >1 mg/dl, blood urea nitrogen >30 mg/dl, or total bilirubin >4 mg/dl should receive 1.5 g albumin per kg body weight within 6 hours of detection and 1.0 g/kg on day 3. EASL Guidelines Class I, Level B Until more information is available, we recommend that all patients who develop SBP should be treated with broad spectrum antibiotics and intravenous albumin (1.5 g/kg at diagnosis and 1g/kg on day 3). Albumin 7,8 Overview Albumin is an endogenous protein 66,500 kda in molecular weight that exerts most (70-80%) of the colloid oncotic pressure in blood plasma Derived for pharmaceutical use from pooled human plasma Distributes widely in the vasculature and extravascular space Acts as a transport molecule for a variety of endogenous substances and drugs, including: o Nitric oxide o Fatty acids o Metals o Cholesterol o Phenytoin (recall corrected phenytoin level in hypoalbuminemia) o Digoxin Exerts a strong oncotic pressure and can serve as a vascular volume expander (this is its FDA labeled indication) Serves as a thiol sink and is the major contributor of extracellular thiols, which are scavengers of reactive oxygen and nitrogen species Available in the US as a 5% and 25% solution Mechanism of Action in the Prevention of Hepatorenal Syndrome 5
6 Albumin's function as a plasma volume expander may serve to compensate for the decrease in SVR caused by cirrhosis and portal hypertension (this is likely the primary mechanism of action in the prevention of hepatorenal syndrome) Antioxidant effects may play a role by decreasing the release of vasodilators from cirrhotic liver tissue Albumin may bind bacterial endotoxins and DNA fragments that contribute to hepatorenal syndrome via bacterial translocation As discussed in guidelines, albumin must be combined with a vasoconstrictor to maximize effectiveness in the treatment of SBP Costs and Adverse Effects Available as a generic: AWP for 25g of 25% albumin is $64.50 For reference, a guideline-recommended course of albumin in a 70kg SBP patient would cost roughly $450 at AWP Contraindications and Precautions o Contraindicated in cardiac failure: leads to circulatory overload o Use with caution in patients with renal or hepatic impairment, as protein load may precipitate azotemia or encephalopathy o Pulmonary or peripheral edema may result from overly rapid infusion o Hypersensitivity reactions have occurred o Blood product: though pasteurized, cannot rule out transmission of infective agents Literature Review Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis 9 Objective: To determine whether plasma volume expansion with albumin could prevent the impairment of renal function and reduce mortality in patients with SBP. Methods Multicenter, randomized, controlled trial Inclusion and exclusion criteria (notice parallels to hepatorenal syndrome and SBP diagnostic criteria) o Ascitic fluid PMN count > 250 cells/mm 3 o Absence of findings suggestive of secondary peritonitis o Absence of shock, GI bleed, grade 3 or 4 hepatic encephalopathy, HIV infection, cardiac failure, and other infections o Serum creatinine no more than 3 mg/dl o Severe dehydration within one week of diagnosis of peritonitis, as evaluated clinically or by CVP < patients were evaluated, 126 were included Patients were randomized to either renally adjusted cefotaxime or renally adjusted cefotaxime plus 20% albumin 1.5g/kg on day 1 and 1g/kg on day 3 of enrollment Follow-up lasted 90 days from the enrollment period Renal impairment at the time of enrollment was defined as a BUN of > 40 mg/dl or a serum creatinine of > 1.5 mg/dl In patients without renal impairment at baseline, a 50% increase in BUN or serum creatinine to levels above 40 mg/dl and 1.5 mg/dl respectively was diagnostic for renal impairment during treatment 6
7 For patients with renal impairment at baseline, simply a 50% increase in BUN or serum creatinine was diagnostic for worsening renal failure 50 patients in each group were required for an 80% power to detect a 25% difference in the rate of renal failure Results Clinical outcome according to assigned treatment. Cefotaxime Outcome Variable Cefotaxime (n = 63) plus albumin (n = 63) p Value Resolution of infection - No. (%) 59 (94) 62 (98) 0.36 Duration of antibiotic therapy - days 6±1 5±1.48 Paracentesis for ascites after resolution of infection - 16 (25) 14 (22).83 no. (%) Hospital stay - days 13±1 14±1.48 Renal impairment - no. (%) 21 (33) 6 (10) 0.01 Death - no (%) In hospitals At three months 18 (29) 26 (41) In-hospital mortality according to variables with independent predictive value. Variable Bilirubin <4 mg/dl Prothrombin time 60% of control Prothrombin time < 60% of control Bilirubin 4 mg/dl Prothrombin time 60% of control Prothrombin time < 60% of control 6 (10) 14 (22) Cefotaxime (n = 63) Cefotaxime plus albumin (n = 63) BUN <30 mg/dl BUN 30 mg/dl BUN <30 mg/dl BUN 30 mg/dl no. of patients who died/total no. (%) 0/13 0/7 3/6 (50) 2/8 (25) 0/10 0/14 1/10 (10) 2/5 (40) 1/3 (33) 1/5 (20) 0/0 0/1 4/12 (33) 7/9 (78) 0/16 3/7 (43) Total 5/35 (14) 13/28 (46) 0/40 6/23(26) Mortality and progression to renal failure were significantly reduced in the cefotaxime plus albumin group Importantly, BUN > 30 mg/dl, bilirubin > 4mg/dL, and prothrombin time > the control group were independent predictors of mortality All patients in the trial had a baseline serum creatinine of 1.1±0.1 (control group) or 1.2±0.1 (treatment group) 89% of patients who developed renal failure and 16% of patients who did not develop renal failure had died at 3-month followup Discussion and Conclusions 7
8 The authors conclude that albumin plus empiric antibiotic treatment is more effective at reducing mortality and progression to renal failure in patients with SBP than empiric antibiotics alone The trial helps confirm that progressive renal failure and hepatorenal syndrome are indicative of a poor prognosis Trial strengths o Randomized and adequately controlled o Endpoints and inclusion criteria consistent with the disease states being studied (PMN count in ascitic fluid, serum creatinine cutoffs, etc.) o Demonstrated a mortality benefit o Appropriate statistical analysis Trial weaknesses o Benefit was most apparent in patients with BUN > 30 mg/dl and bilirubin > 4mg/dL, and only patients with a serum creatinine above 1.0 were included in the trial o Does not shed light on whether albumin is unique or other plasma volume expanders would be effective for the same purpose (the authors address this in their discussion) o Control patients may have been sicker Restricted use of albumin for spontaneous bacterial peritonitis 10 Objective: To assess whether albumin treatment is needed in all cases of SBP or whether a risk stratification strategy is desirable. Methods A 28 patient prospective case series in two medical centers Patients with a bilirubin > 4 or a serum creatinine > 1.0 were treated with albumin 1.5g/kg on day 1 and 1g/kg on day 3 of treatment along with empiric antibiotics Low-risk patients (serum creatnine < 1.0 and bilirubin < 4) were treated only with empiric antibiotic therapy Results Selected clinical characteristics of patients at diagnosis of spontaneous bacterial peritonitis episodes who did receive (A) and who did not receive (B) albumin. A (n = 26) B (n = 18) p Value Total bilirubin(mmol/l) 115 (12-395) 39 (14-67) <0.001 BUN (mg/dl) 28.5 (7-74) 18(5-48) Creatinine (mmol/l) 124 (35-327) 80 (53-106) In the low-risk group, SBP resolved in all patients and no patients developed renal impairment. In the high-risk group, 12 patients developed renal impairment and five patients died. Discussion and Conclusions The authors conclude that albumin is not needed in all SBP patients Strengths o Used parameters based on the single randomized, controlled trial performed for this intervention o Used established guidelines for diagnosis and treatment of SBP and hepatorenal syndrome 8
9 o Calculated p values Weaknesses o No control group o Small case series Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials 11 Objective: To quantify the effect of albumin infusion on renal impairment and mortality in patients with SBP. Methods A meta-analysis limited to only randomized, controlled trials evaluation albumin in SBP patients o No language or time period restrictions All three investigators independently determined trial inclusion eligibility Endpoints of the analysis were renal impairment (as defined by the included trials) and mortality Heterogeneity was judged using the Cochran Q test and the I 2 test Results of the trials were combined under a fixed-effects model Results Renal impairment. Confidence interval (CI) is shown by error bars. Data points for individual trials scaled accordingly to meta-analytic weight. 9
10 Improvement in the incidence of renal impairment and mortality were shown o Removing either of the two most heavily weighted studies did not change the overall conclusion No differences shown between subgroups, however, a non-significant increase was seen in the incidence of renal impairment and mortality in patients with BUN > 30 mg/dl and/or bilirubin > 4 Discussion and Conclusions The authors conclude that albumin is effective for prevention of renal failure and mortality in SBP patients with cirrhosis. Strengths o Relied only on randomized, controlled trials o Appropriate statistical analysis o Robust results Weaknesses o Small sample size o 3 out of the 4 trials were not blinded Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study 12 Objective: To determine if albumin has beneficial effects outside of patients with cirrhosis that develop SBP. Methods Single center, randomized, controlled trial Inclusion criteria o Cirrhosis, diagnosed by liver biopsy or by clinical findings according to published guildelines o Presence of infection, diagnosed by cultures or clinical suspicion with at least one of the following: PMN count > 10,000 cells/mm 3 or 50% increase from baseline with a final value above 8,000 cells/mm 3 5% or greater bands Temperature > 37.5 C Exclusion criteria o GI bleed o Previous antibiotic treatment 10
11 o Malignancy o HIV infection o Presence of shock 51 patients were randomized to each group (control and treatment) Control group received only empiric antibiotic treatment with: o IV ceftriaxone for UTI, sepsis of unknown origin, or spontaneous bacteremia o IV ceftriaxone plus cloxacillin or Augmentin for SSTI o IV ceftriaxone and a macrolide or levofloxacin (with clindamycin for aspiration) for CAP o IV ceftazadime plus ciprofloxacin for HAP o IV vancomycin and ceftazadime for catheter-related infections Intervention group received empiric antibiotic therapy plus albumin 1.5g/kg on day 1 and 1g/kg on day 3 Primary endpoint was 3-month mortality Secondary endpoints were the effects on serum creatinine, percentage of patients who developed renal failure, and effects on circulatory and vasoactive variables Study sized for an 80% power to detect a 30% difference in survival rates Results Three-month probability of survival. Univariate analysis of the 3-month survival according to baseline variables, characteristics of infection, and occurrence of renal failure. 11
12 Variable Alive (n = 79) Death (n = 18) p Value Age (yr) 55 ± ± Ascites at inclusion 54 (68%) 17 (94%) Hepatic encephalopathy at inclusion 24 (30%) 11 (61%) Nosocomial infection 11 (14%) 10 (56%) < Serum bilirubin (mg/dl) 3.5 ± ± Serum albumin (mg/dl) 29 ± 6 26 ± Serum creatinine (mg/dl) 1.2 ± ± BUN (mg/dl) 24 ± ± Renal failure during infection 15 (19%) 10 (56%) Overall, there were no significant differences in the unadjusted 3-month mortality rates between the control and intervention groups (80% survival in the control group vs. 82.6% survival in the intervention group) Significance was shown when the results were adjusted for variables shown in univariate analysis to have independent predictive value Differences in the incidence of renal failure and in serum creatnine concentrations between the control and intervention groups did not reach statistical significance o Compared to SBP patients, renal failure did not occur as often in the control group of this study o Mortality was also lower in the control group compared to SBP patients not treated with albumin Discussion and Conclusions The authors conclude that albumin treatment in patients with bacterial infections other than SBP is not associated with a significant decrease in either 3 month mortality or the incidence of renal failure The overall incidence of renal failure and mortality in the trial's control group reveals that the overall difference in prognosis between SBP and other bacterial infections may help explain the negative results of this trial Strengths o Randomized and controlled o Used mortality as an endpoint o Statistical analysis appropriate, including power calculation, and did not overstep with conclusions based on post-hoc adjustment of results Weaknesses o Power estimate greatly overstated the actual effect size o Needed to adjust results for statistical significance Conclusions Albumin is effective for the prevention of progression to hepatorenal syndrome and renal failure in SBP patients There is a small body of evidence that suggests that albumin is not needed in all SBP patients, but more study is needed No evidence to suggest that albumin is effective in other bacterial infections in cirrhotic patients More evidence is needed to inform about the optimal dose of albumin in SBP patients o Trials underway (ClinicalTrials.gov: NCT ) 12
13 References 1. Diagnosis, prevention, and treatment of hepatorenal syndrome in cirrhosis. Salerno F, Gerbes A, Gines P, et al. Gut. 2007;56: Mechanisms promoting bacterial translocation from the gastrointestinal tract. Berg RD. Adv Exp Med Biol 1999;473: Spontaneous bacterial peritonitis: recent data on incidence and treatment. Mansour PA, Atreja A, Zein NN. Cleve Clin J Med. 2004;71(7): Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Follo A, Llovet JM, Navasa M, et al. Hepatology 1994;20: Management of adult patients with ascites due to cirrhosis: update Runyon, BA for the AASLD. Hepatology 2013;57(4): EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. EASL. Hepatology 2010;53: Albumin. Lexi-Comp Online, Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; Accessed September 22, Albumin for end-stage liver disease. Lee JS. Korean J Intern Med 2012(27): Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Sort P, Navasa M, Arroyo V, et al. N Engl J Med 1999;341: Restricted use of albumin for spontaneous bacterial peritonitis. Sigal SH, Stanca SM, Fernandez J, et al. Gut 2007;56(4): Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Salerno F, Navickis RJ, Wilkes MM. Clin Gastroenterol Hepatol 2013;11(2): Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. Guevara M, Terra C, Nazar A, et al. Hepatology 2012;57:
14 Appendix A: Included Trials in the Meta-analysis from Salerno et al. Table 1. Included Trials Trial N Age (SD) Sort et al, 1999 Xue et al, 2002 Fernandez et al, 2005 Chen et al, (7.9) Male, % Ethnicity Etiology Treatment regimen 64.3 Caucasian 29.4% alcohol, 70.6% other Cefotaxime intravenously dosed according to creatinine without vs with 1.5g/kg 20% albumin within first 6 h plus 1.0 g/kg on day Chinese - Ceftriaxone intravenously dosed according to creatinine without vs with g/kg 20% albumin within first 6 h and every third day for 21 days (9.5) (11.5) 55 Caucasian 60.0% HCV, 40.0% other 60 Chinese 60.0% HBV<comma> 23.3% HCV<comma> 16.7% alcohol Ceftriaxone intravenously 2 g at diagnosis and then 1 g/d plus 1.5 g/kg at baseline and 1.0g/kg on day 3 of 20% albumin vs 6% HES 200/0.5 Cephalosporins without vs with 50 ml 20% albumin (0.14 g/kg∠1 for a 70-kg patient) on days 1â 3 14
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many
More informationCIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationRenal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:260 265 Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis PUNEETA TANDON*,
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationSign up to receive ATOTW weekly -
HEPATORENAL SYNDROME ANAESTHESIA TUTORIAL OF THE WEEK 240 10 TH SEPTEMBER 2011 Gerry Lynch Rotherham General Hospital Correspondence to gerry.lynch@rothgen.nhs.uk QUESTIONS Before continuing, try to answer
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationAdrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT
20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit
More informationOptimal management of ascites
Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationTREBALL DE RECERCA. Facultat de Medicina Departament de Medicina Hospital de la Santa Creu i Sant Pau
TREBALL DE RECERCA INSUFICIÈNCIA RENAL I MORTALITAT DELS PACIENTS CIRRÒTICS AMB PERITONITIS BACTERIANA ESPOTÀNIA I BAIX RISC DE MORTALITAT NO TRACTATS AMB ALBÚMINA. Facultat de Medicina Departament de
More informationElevated Creatinine in a Patient With Cirrhosis
REVIEW Elevated Creatinine in a Patient With Cirrhosis Heather L. Klavan, M.D., and Brett E. Fortune, M.D., M.S. Elevation in serum creatinine is a common laboratory finding for patients with cirrhosis
More informationHepatology on the AMU
Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge Is liver disease relevant to me? Williams R, Lancet 2014
More informationSYSTEMATIC REVIEWS AND META-ANALYSES
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:123 130 SYSTEMATIC REVIEWS AND META-ANALYSES Fasiha Kanwal, Section Editor Albumin Infusion Improves Outcomes of Patients With Spontaneous Bacterial Peritonitis:
More informationCirrhosis Complications
Cirrhosis Complications and Spontaneous Bacterial Peritonitis While these complications greatly increase mortality from decompensated cirrhosis, effective treatment is possible with early diagnosis. Vigilant
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationAcute Liver Failure: Supporting Other Organs
Acute Liver Failure: Supporting Other Organs Michael A. Gropper, MD, PhD Professor of Anesthesia and Physiology Director, Critical Care Medicine University of California San Francisco Acute Liver Failure
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationDiagnostic Value of Leucocyte Esterase Reagent Strip Test in Cirrhotic Patients with Ascites for Early Detection of Spontaneous Bacterial Peritonitis
Diagnostic Value of Leucocyte Esterase Reagent Strip Test in Cirrhotic Patients with Ascites for Early Detection of Spontaneous Bacterial Peritonitis Sunil Agrawal, Barjatya H.C. Introduction The word
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationDialyzing challenging patients: Patients with hepato-renal conditions
Dialyzing challenging patients: Patients with hepato-renal conditions Nidyanandh Vadivel MD Medical Director for Living kidney Donor and Pancreas Transplant Programs Swedish Organ Transplant, Seattle Acute
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationFactors Affecting Mortality and Morbidity of Patients With Cirrhosis Hospitalized for Spontaneous Bacterial Peritonitis
POSter PreSentAtIOn Factors Affecting Mortality and Morbidity of Patients With Cirrhosis Hospitalized for Spontaneous Bacterial Peritonitis Fatih Ensaroğlu, 1 Murat Korkmaz, 1 Ali Ümit Geçkil, 2 Serkan
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use
Approved by NPPEAG 28 May 2018 Reviewed 1 June 2018 To be reviewed 1 June 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group Clinical Guidelines for Human Albumin Use 1 National
More informationReview article: hepatorenal syndrome definitions and diagnosis
Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 24 28. Review article: hepatorenal syndrome definitions and diagnosis R. MOREAU & D. LEBREC Laboratoire d Hémodynamique Splanchnique et de Biologie Vasculaire,
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use
Approved by NPPEAG 10 December 2010 Reviewed 1 June 2012 To be reviewed 1 June 2014 Developed for Scotland by the National Plasma Product Expert Advisory Group Clinical Guidelines for Human Albumin Use
More informationTherapy Insight: management of hepatorenal syndrome
Therapy Insight: management of hepatorenal syndrome Andrés Cárdenas and Pere Ginès* SUMMARY Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS.
ACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS. Vicente Arroyo 1, 2, Rajiv Jalan 2, 3 1 Institut de Investigacions Biomèdiques August Pi I Sunyer. University of Barcelona.
More informationLiver-Kidney Crosstalk in Liver and Kidney Diseases
Liver-Kidney Crosstalk in Liver and Kidney Diseases Sundararaman Swaminathan MD Associate Professor Division of Nephrology University of Virginia Health System Charlottesville, VA Hepatonephrologist busily
More informationEASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 Ascites is the
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationASCITES. Dr KS Cheung Queen Mary Hospital
ASCITES Dr KS Cheung Queen Mary Hospital Outline Pathophysiology Differential diagnosis of ascites Diagnostic paracentesis Ascitic fluid analysis Management of Ascites Management of spontaneous bacterial
More informationPrognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis
GASTROENTEROLOGY 2011;140:488 496 Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis MARTA MARTÍN LLAHÍ,*,, MÓNICA GUEVARA,*,, ALDO TORRE,*,, CLAUDIA FAGUNDES,*,, TEA RESTUCCIA,*,,
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationHepatorenal syndrome
Annals of Hepatology 2003; 2(1): January-March: 23-29 Concise Review Annals of Hepatology Hepatorenal syndrome Andrés Cárdenas, M.D., 1 Vicente Arroyo, M.D. 2 Abstract Hepatorenal syndrome is complication
More informationSupplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:
Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned
More informationSetting The setting was secondary care. The economic study was carried out in Turkey.
Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis Tuncer I, Topcu N, Durmus A, Turkdogan M K Record Status This is a critical abstract
More informationAscites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management
Journal of Hepatology 38 (2003) S69 S89 www.elsevier.com/locate/jhep Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management Vicente Arroyo*, Jordi Colmenero
More informationRENAL DISEASE IN END STAGE LIVER DISEASE
RENAL DISEASE IN END STAGE LIVER DISEASE Mitchell L Shiffman, MD Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need Mitchell L Shiffman, MD POTENTIAL CONFLICTS
More informationCirrhosis is an important cause of morbidity and mortality
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:487 493 Role of Fluoroquinolones in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis: Meta-Analysis ROHIT LOOMBA,* ROBERT WESLEY, ANDREW BAIN,*
More informationHow and why to measure renal function in patients with liver disease?
ow and why to measure renal function in patients with liver disease? P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationWhat would be the response of the sympathetic system to this patient s decrease in arterial pressure?
CASE 51 A 62-year-old man undergoes surgery to correct a herniated disc in his spine. The patient is thought to have an uncomplicated surgery until he complains of extreme abdominal distention and pain
More informationDiagnosis of Spontaneous Bacterial Peritonitis by Identification of 16s rrna Genes in Liver Cirrhosis Patients
Med. J. Cairo Univ., Vol. 83, No. 2, December: 209-214, 2015 www.medicaljournalofcairouniversity.net Diagnosis of Spontaneous Bacterial Peritonitis by Identification of 16s rrna Genes in Liver Cirrhosis
More informationAlpha-1 Antitrypsin Deficiency: Liver Disease
Alpha-1 Antitrypsin Deficiency: Liver Disease Who is at risk to develop Alpha-1 liver disease? Alpha-1 liver disease may affect children and adults who have abnormal Alpha-1 antitrypsin genes. Keys to
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationCase Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis
Diagnostic Problems in Hepatology 181 Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis Carmen Sendra, MD 1 Javier Ampuero, MD, PhD 1,2 Álvaro
More informationAlbumin Regulation and Reimbursement
FACULTY OF MEDICINE, DENTISTRY AND HEALTH SCIENCES Albumin Regulation and Reimbursement ALBERT FARRUGIA, ADJUNCT PROFESSOR, DEPARTMENT OF SURGERY Disclosures Compensated contractual services to the biotherapeutics
More informationFluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE
Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE In critically ill patients: too little fluid Low preload,
More informationOriginal Article. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial
30 Journal of The Association of Physicians of India Vol. 64 September 2016 Original Article Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial
More informationRenal dysfunction is a common complication of
GASTROENTEROLOGY 2013;145:1280 1288 New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection FLORENCE WONG, 1 JACQUELINE G. O LEARY,
More informationNew Medicine Assessment
New Medicine Assessment Co-trimoxazole (Septrin ) Prophylaxis of Primary and Secondary Spontaneous Bacterial Peritonitis (SBP) Recommendation: Amber 2 Co-trimoxazole is recommended as: a second-line option
More informationCONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number:
Cirrhosis Care Bundle CONTROLLED DOCUMENT CATEGORY: Clinical Guidelines CLASSIFICATION: Clinical Controlled Document CG201 Number: Version Number: 1 Controlled Document Clinical Guidelines Group Sponsor:
More informationAcute Kidney Injury. I. David Weiner, M.D. Division of Nephrology, Hypertension and Transplantation University of Florida and NF/SGVHS
Acute Kidney Injury I. David Weiner, M.D. Division of Nephrology, Hypertension and Transplantation University of Florida and NF/SGVHS 374-6102 David.Weiner@medicine.ufl.edu www.renallectures.com Concentration
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationAscites, a New Cause for Bilateral Hydronephrosis: Case Report
Case Study TheScientificWorldJOURNAL (2009) 9, 1035 1039 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.112 Ascites, a New Cause for Bilateral Hydronephrosis: Case Report D. Jain*, S. Dorairajan, and
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationManagement of Nephrotic Syndrome
Management of Nephrotic Syndrome 1. Introduction Incidence 2-4/100,000. Boys > girls 3:2; age of onset 2-6 years 80% of cases in children is due to minimal change (MCD) of which 80% will respond to steroid
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationDecompensated chronic liver disease
Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation
More informationHepatorenal Syndrome: Clinical Considerations
426 Medicine Update 74 Hepatorenal Syndrome: Clinical Considerations VIVEK A SARASWAT, RAVI RATHI BACKGROUND The hepatorenal syndrome (HRS) is a life-threatening form of functional renal failure associated
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationThe renal resistive index is a non-invasive indicator of hepatorenal syndrome in cirrhotics
Journal of Advanced Clinical & Research Insights (2016), 3, 23 27 ORIGINAL ARTICLE The renal resistive index is a non-invasive indicator of hepatorenal syndrome in cirrhotics Mohsin Aslam, S. Ananth Ram,
More informationCorresponding Author: Dr. Ali Saqib, Department of Medicine, Madina Teaching Hospital, Faisalabad.
Original Article FREQUENCY OF SPONTANEOUS BACTERIAL PERITONITIS (SBP) IN CIRRHOTIC PATIENTS WITH ASCITES DUE TO HEPATITIS B AND C Ali Saqib 1, Rizwan Rasul Khan 2, Zahid Masood 3, Irshad ul Haque 4 1 Assistant
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationSHOCK AETIOLOGY OF SHOCK (1) Inadequate circulating blood volume ) Loss of Autonomic control of the vasculature (3) Impaired cardiac function
SHOCK Shock is a condition in which the metabolic needs of the body are not met because of an inadequate cardiac output. If tissue perfusion can be restored in an expeditious fashion, cellular injury may
More informationClinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis
ORIGINAL ARTICLE 2018 Mar 6. [Epub ahead of print] Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis Jungok Kim 1, Cheol-In
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationOnline Supplement for:
Online Supplement for: INFLUENCE OF COMBINED INTRAVENOUS AND TOPICAL ANTIBIOTIC PROPHYLAXIS ON THE INCIDENCE OF INFECTIONS, ORGAN DYSFUNCTIONS, AND MORTALITY IN CRITICALLY ILL SURGICAL PATIENTS A PROSPECTIVE,
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More information